Drugs / MK-7262
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07619443 | Jul → Sep 2026 overdue | — | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07614984 | Jun 2026 → Oct 2027 expected | lipoprotein, variant of beta | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-7262 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07614984 ↗ |
| Route | Oral | “Participants will receive MK-7262 + enlicitide placebo orally once daily (QD) for up to approximately 12 weeks of treatment.” NCT07614984 ↗ |